Modra Pharmaceuticals B.V., a clinical stage company focused on oncology, has secured $38.0 million in new investment capital. This funding round marks a significant milestone for the company as it continues to advance its innovative approach to cancer treatment.
Modra Pharmaceuticals, a spin-out from the Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL) and MC Slotervaart in Amsterdam, specializes in developing new treatment paradigms by enabling the oral bioavailability of existing anticancer drugs. This strategy, referred to as "the iv to oral switch," aims to improve cancer therapy and supportive care by offering more convenient and accessible treatment options for patients. The company currently has several products in preclinical and clinical development, including oral formulations of docetaxel and paclitaxel.
The newly raised capital is intended to accelerate the development of Modra Pharmaceuticals' pipeline. Specifically, the funds will support the progression of its lead product candidates through clinical trials and further expand its research and development efforts. This investment is crucial for a clinical-stage company like Modra, as it provides the necessary resources to move promising drug candidates closer to market.
This funding underscores investor confidence in Modra Pharmaceuticals' platform and its potential to significantly impact cancer care. The company is poised to continue its mission of transforming how existing anticancer drugs are administered, with the ultimate goal of enhancing patient outcomes and quality of life. Modra Pharmaceuticals anticipates that this capital will enable substantial progress in its clinical programs and contribute to its long-term growth objectives.
.png&w=3840&q=75)
